# Jornay PM

### (methylphenidate delayed and extended release capsules)

<table border="1" id="bkmrk-prescribing-info" style="border-collapse: collapse; width: 100%; border-width: 0px; background-color: rgb(230, 126, 35);"><tbody><tr><td style="background-color: rgb(194, 224, 244); border-width: 0px; width: 50%;">[**Full Prescribing Information**](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d95dede0-b1ff-4489-8f91-3bbe122852bf&type=display)</td><td class="align-right" style="background-color: rgb(251, 238, 184); border-width: 0px; width: 50%;">[**DailyMed Drug Information**](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d95dede0-b1ff-4489-8f91-3bbe122852bf)</td></tr></tbody></table>

---

**Forms/Strengths**

- **Capsules:** 20 mg, 40 mg, 60 mg, 80 mg, 100 mg

---

### **Dosing**

- **Age:** ≥ 6 y/o
- **Onset:** delayed until early morning (~10-12 hours after evening dose)
- **Duration:** 12-14 hours
- **Considerations:** Take in the evening between 6:30-9:30 pm. Capsules can be opened and sprinkled on applesauce.
- **Initial Dose:** 20 mg once daily in the evening
- **Titration:** 20 mg weekly
- **Max Dose:** 60 mg/day

---

### **Quick Facts**

- Inhibits dopamine/norepinephrine reuptake
- Enhances focus, attention, and impulse control
- Extended-release methylphenidate with delayed-release profile designed for bedtime dosing
- Unique evening dosing provides early morning onset and sustained symptom control throughout the day
- Common side effects: decreased appetite, insomnia, headache, gastrointestinal discomfort

---

### **Indications**

- ADHD** (ICD-10: F90.0)

---

### **Off-Label Uses**

- 

---

### **How to Take**

- Take **once daily in the evening** between **6:30 PM and 9:30 PM** to allow for morning symptom control.
- Can be taken **with or without food**; high-fat meals may delay absorption.
- Swallow the **capsule whole**; do not crush or chew.
- If needed, the **capsule may be opened and sprinkled on applesauce**—consume immediately without chewing.

---

### **Side Effects**

- 

---

### **Monitoring / Labs**

- **Cardiovascular**: Baseline and routine monitoring of heart rate and blood pressure.
- **Growth in Pediatrics**: Regular monitoring of height and weight to detect growth suppression.
- **Psychiatric Symptoms**: Observe for mood changes, anxiety, or psychosis.
- **Abuse Potential**: Monitor for misuse or diversion.

---

### **Education**

- **When to Call the Doctor:**
    
    
    - Severe **mood changes, aggression, or suicidal thoughts**.
    - Chest pain, rapid heartbeat, shortness of breath (**cardiovascular concerns**).
    - Uncontrolled movements, tics, or worsening anxiety.
    - Numbness, coldness, or color changes in fingers or toes (**circulatory issues**).
    - Unexplained weight loss or **delayed growth in pediatric patients**.
- **Safety Tips:**
    
    
    - **Monitor blood pressure and heart rate**, especially in patients with cardiovascular risk.
    - Use caution in patients with **anxiety, bipolar disorder, or psychosis**, as symptoms may worsen.
    - Avoid **caffeine and other stimulants**, which may amplify side effects.
    - Ensure **adequate hydration and nutrition**, as appetite suppression is common.
    - **Tapering may be required** if discontinuing after long-term use.
- **Parent Tips for Pediatric Patients:**
    
    
    - **Encourage a nutrient-dense diet** to counteract appetite suppression.
    - Administer **exactly as prescribed in the evening** for proper morning symptom control.
    - Monitor **school performance and behavioral changes**.
    - Observe for **sleep disturbances**; adjust timing if necessary.
    - Communicate regularly with **teachers and caregivers** about medication effects.
- 

---

### **Additional Information**

- **Contraindications:**
    
    
    - **Hypersensitivity** to methylphenidate or formulation components.
    - **Use within 14 days of MAOI therapy** (risk of hypertensive crisis).
    - Symptomatic **cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma**.
    - **History of substance use disorder**, unless benefits outweigh risks.
- **Pregnancy:**
    
    
    - **Category C**; use only if benefits outweigh risks.
    - May cause **neonatal withdrawal symptoms** or **low birth weight**.
- **Lactation:**
    
    
    - **Excreted in breast milk**; **not recommended** due to potential infant exposure.
- **Drug Interactions:**
    
    
    - **Serotonergic drugs** (e.g., SSRIs, SNRIs, MAOIs) increase **serotonin syndrome risk**.
    - **Acidifying agents** (e.g., ascorbic acid) may reduce drug absorption.
    - **Alkalinizing agents** (e.g., sodium bicarbonate) may increase methylphenidate levels.
    - May potentiate **hypertensive effects** of certain medications (e.g., decongestants, beta-agonists).